Sanofi Invests €66 Million in R&D Hub in China

(Credit: Sanofi)

International biopharma, Sanofi is to launch a global R&D Operations Hub in China, with a specialised focus on digitalisation and big data analysis. 

With an investment of €66 million, the hub will support clinical research and development of Sanofi’s innovative drugs by focusing on the management of global multi-center clinical trials data and files. 

The new hub further reinforces Sanofi’s presence in China as the third pillar of Sanofi Global Clinical Sciences and Operations, joining facilities in France and the U.S. 

Sanofi Shells Out $11.6 Billion for Hemophilia Drugmaker, Bioverativ

“Through this new hub, we will take full advantage of our global experience and R&D capabilities together with local scientific research strengths to further improve innovation,” said Zhang Ji, PhD, Senior VP and Global Head of Sanofi R&D Operations. 

“Our goal is to link China’s innovative achievements with the global ecosystem and develop innovative drugs in China that could benefit patients around the world.” 

The hub will target diseases that affect millions of people across Sanofi’s therapeutic areas: diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis and neurology. 

Sanofi is One Step Closer to Challenging Blockbuster Diabetes Sales from its Rival

It will leverage biological technology for polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies, and plans to recruit 300 local pharmaceutical R&D professionals by 2020.